Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 280 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Streptococcus pneumoniae Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

NCT07059182
View directory record Official record
Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions
Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo
Biological · Drug
Lead sponsor
Serum Life Science Europe GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

NCT03828617
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
20vPnC, 13vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,710 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
21
States / cities
Anaheim, California • Sacramento, California • San Jose, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 2, 2026, 8:17 AM EDT
Completed No phase listed Observational

A Study To Examine Serologic Response In Hospitalized Patients Receiving Polyvalent Pneumococcal Vaccine

NCT00955851
View directory record Official record
Conditions
Pneumonia
Interventions
Pre and post vaccination titers
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2010 · Synced Sep 2, 2026, 8:17 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06736041
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,714 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
66
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 2, 2026, 8:17 AM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

NCT03376477
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GM-CSF vaccine, Lenalidomide, Prevnar13, Placebo Prevnar13, Placebo GM-CSF Vaccine
Biological · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

NCT01702428
View directory record Official record
Conditions
Rubella, Measles, Mumps
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
5,016 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
62
States / cities
Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

NCT01000974
View directory record Official record
Conditions
Haemophilus Influenzae Type b
Interventions
GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,003 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
63
States / cities
Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 2, 2026, 8:17 AM EDT
Active, not recruiting No phase listed Observational

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older

NCT06782282
View directory record Official record
Conditions
Community-Acquired Pneumonia (CAP)
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
22,234,435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 2, 2026, 8:17 AM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

NCT00509106
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

9-valent CRM 197 Pneumococcal

NCT00133549
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
Placebo, PNU-IMUNE®23, Nine-valent pneumococcal conjugate (PNCRM9)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
2
States / cities
Rochester, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

NCT03731182
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Wilmington, Delaware • Atlanta, Georgia • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants

NCT00444457
View directory record Official record
Conditions
Vaccines, Pneumococcal
Interventions
13-valent Pneumococcal Conjugate Vaccine, 7vPnC
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
1,712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Benton, Arkansas • Conway, Arkansas • Fayetteville, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 1 Interventional

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

NCT00000829
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Modulation of Steroid Immunosuppression by Alveolar Efferocytosis

NCT03034642
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pneumonia, Bacterial
Interventions
Bronchoscopy with bilateral bronchoalveolar lavages
Procedure
Lead sponsor
VA Ann Arbor Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 2, 2026, 8:17 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

NCT07794748
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
4,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Lake Forest, California • Walnut Creek, California • Milford, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)

NCT03950622
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13®
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
14
States / cities
Mesa, Arizona • San Diego, California • Hialeah, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Results available

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

NCT01349569
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Allogeneic Myeloma Vaccine, Prevnar-13
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

NCT00129129
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Persistent Readiness Through Early Prediction Immunization Study

NCT05346302
View directory record Official record
Conditions
Inflammatory Response
Interventions
Pneumovax 23, Typhim VI, Saline
Drug · Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 2, 2026, 8:17 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Aerosolized and Intravenous Colistin in Healthy Adults

NCT01863719
View directory record Official record
Conditions
Pathogen Resistance, Pneumococcal Infection, Pneumonia
Interventions
Colistimethate sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 2, 2026, 8:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01312389
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-L/Montanide ISA 51 VG, Ampligen, Prevnar
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

NCT05831124
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control, Standard dose multivalent pneumococcal conjugate vaccine control
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Hialeah, Florida • Hollywood, Florida • Columbia, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 2, 2026, 8:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

NCT02034773
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220, Placebo
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 2, 2026, 8:17 AM EDT